Tag

Bilastine archivos - Page 2 of 2 - Bilastina

The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H1 receptor

By | Articles about Bilastine
Bosma R, van den Bor J, Vischer HF, Labeaga L, Leurs R

Bilastine shows a long drug-target residence time at the H1 receptor (73 ± 5 min) and this results in a prolonged H1 receptor antagonism in vitro (Ca2+ mobilization in Fluo-4 loaded HeLa cells), following a washout of unbound antagonist. Hence, the long residence time of bilastine can explain the observed long duration of drug action in vivo.

This document is only available for registered healthcare professionals

Login
Antihistamínico novel

Bilastine – A Novel Antihistamine for Allergic Rhinitis and Chronic Spontaneous Urticaria

By | Articles about Bilastine
Kraft JN, Sussman GL

Bilastine has a proven, long-term safety record with use by over 71 million patients in over 104 countries. This novel, second generation antihistamine is non-sedating due to the fact that it does not cross the blood brain barrier. As well, bilastine is not metabolized and does not interact with CYP450.

This document is only available for registered healthcare professionals

Login
F1 simulador

Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients

By | Articles about Bilastine
Demonte A, Guanti MB, Liberati S, Biffi A, Fernando F, Fainello M, Pepe P

This study is the first done in patients with allergic rhinitis and/or chronic urticaria using a F1-high speed simulator-driving test evaluating subjects’ performance under bilastine treatment.

This document is only available for registered healthcare professionals

Login
Estudio de bilastina en pacientes japoneses

One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases

By | Articles about Bilastine
Yagami A, Furue M, Togawa M, Saito A, Hide M.

A number of second-generation non-sedating antihistamines are used in clinical practices over the world. However, long-term safety and efficacy have not been proved high level evidence based medicine. 
In conclusion, long-term treatment with bilastine 20 mg once daily for 52 weeks is safe and well tolerated in Japanese patients with hronic spontaneous urticaria (CSU) or pruritus associated with skin diseases. Bilastine improved disease symptoms of both conditions early in treatment, and the efficacy was maintained throughout the treatment.

This document is only available for registered healthcare professionals

Login
bilastina en pacientes japoneses

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects

By | Articles about Bilastine
Togawa M, Yamaya H, Rodríguez M, Nagashima H.

Bilastine exhibits similar single- and multiple-dose pharmacokinetic and pharmacodynamic characteristics in healthy Japanese subjects compared with those observed in Caucasian subjects in previous studies.

This document is only available for registered healthcare professionals

Login
Bilastina y pacientes japoneses

Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study

By | Articles about Bilastine
Okubo K, Gotoh M, Asako M, Nomura Y, Togawa M, Saito A, Honda T, Ohashi Y.

After 2-week treatment period, bilastine 20 mg once daily was effective and tolerable in Japanese patients with perennial allergic rhinitis (PAR), and exhibited a rapid onset of action.

This document is only available for registered healthcare professionals

Login
Estudio bilastina en niños de 2 a 12 años

Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases

By | Articles about Bilastine
Novák Z, Yáñez A, Kiss I, Kuna P, Tortajada-Girbés M, Valiente R; “Bilastine Paediatric Safety Study Group”.

Bilastine 10 mg had a safety and tolerability profile similar to that of placebo in children aged 2 to <12 years with allergic rhinoconjunctivitis or chronic urticaria.

This document is only available for registered healthcare professionals

Login

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.

ACEPTAR